Next Article in Journal
Too Much of a Good Thing? Exercise Dependence in Endurance Athletes: Relationships with Personal and Social Resources
Next Article in Special Issue
Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
Previous Article in Journal
“People Associate Us with Movement so It’s an Awesome Opportunity”: Perspectives from Physiotherapists on Promoting Physical Activity, Exercise and Sport
Previous Article in Special Issue
Universal Access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How Well Are We Doing?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 18
Issue 6
10.3390/ijerph18062965
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018

by
Zayniddin Sayfutdinov
1,*,
Ajay Kumar
2,3,4,
Dilyara Nabirova
5,
Jamshid Gadoev
6,
Laziz Turaev
1,
Sanjar Sultanov
1,
Sevak Alaverdyan
7 and
Nargiza Parpieva
8
1
National Reference Laboratory, Tashkent 100086, Uzbekistan
2
International Union Against Tuberculosis and Lung Disease, South-East Asia Office, New Delhi 110016, India
3
International Union Against Tuberculosis and Lung Disease, 75006 Paris, France
4
Yenepoya Medical College, Yenepoya (Deemed to be University), Mangaluru 575018, India
5
United States Centers for Disease Control and Prevention, Central Asia Region, Almaty A25T0A1, Kazakhstan
6
WHO Country Office in Uzbekistan, Tashkent 700029, Uzbekistan
7
Bielefeld Graduate School of Economics and Management (BiGSEM), Bielefeld University, Universitätsstraße, 33615 Bielefeld, Germany
8
National Tuberculosis Programme, Ministry of Health, Tashkent 100086, Uzbekistan
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(6), 2965; https://doi.org/10.3390/ijerph18062965
Submission received: 18 February 2021 / Revised: 10 March 2021 / Accepted: 11 March 2021 / Published: 14 March 2021
(This article belongs to the Collection Operational Research to Inform Programmatic Approaches to Management of Tuberculosis in Uzbekistan)
Versions Notes

Abstract

Tuberculosis patients “resistant to isoniazid and susceptible to rifampicin (Hr-TB)” remain neglected, despite a high burden and poor outcomes. The World Health Organization (WHO) recommends a 6 month regimen consisting of levofloxacin, rifampicin, ethambutol, and pyrazinamide (LRZE) to treat Hr-TB. In contrast, Uzbekistan uses a 9 month regimen (LRZE plus a second-line injectable in the first 3 months). We aimed to assess the treatment outcomes of this novel regimen among Hr-TB patients treated in two regions of Uzbekistan (Fergana and Bukhara) in 2017–2018. We conducted a cohort study involving secondary analysis of routine surveillance data. Of 132 Hr-TB patients, 105 (80%) were successfully treated. Death was the predominant unsuccessful outcome (13, 10%) followed by “treatment failure” (10, 8%) and “lost to follow-up” (4, 2%). High treatment success is an indicator of the potential effectiveness of the novel regimen and adds to the limited global evidence on this issue. However, the sample size was small and there was no comparison group. Since the study was conducted in two regions of Uzbekistan only, the findings have limited generalizability. We recommend future research using an adequate sample size and an appropriate study design (randomized controlled trial or prospective cohort with a control group receiving the WHO-recommended regimen).
Keywords: Central Asia; operational research; Hr-TB; isoniazid resistance; treatment outcome; mono resistance; SORT IT (Structured Operational Research Training Initiative) Central Asia; operational research; Hr-TB; isoniazid resistance; treatment outcome; mono resistance; SORT IT (Structured Operational Research Training Initiative)

Share and Cite

MDPI and ACS Style

Sayfutdinov, Z.; Kumar, A.; Nabirova, D.; Gadoev, J.; Turaev, L.; Sultanov, S.; Alaverdyan, S.; Parpieva, N. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. Int. J. Environ. Res. Public Health 2021, 18, 2965. https://doi.org/10.3390/ijerph18062965

AMA Style

Sayfutdinov Z, Kumar A, Nabirova D, Gadoev J, Turaev L, Sultanov S, Alaverdyan S, Parpieva N. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health. 2021; 18(6):2965. https://doi.org/10.3390/ijerph18062965

Chicago/Turabian Style

Sayfutdinov, Zayniddin, Ajay Kumar, Dilyara Nabirova, Jamshid Gadoev, Laziz Turaev, Sanjar Sultanov, Sevak Alaverdyan, and Nargiza Parpieva. 2021. "Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018" International Journal of Environmental Research and Public Health 18, no. 6: 2965. https://doi.org/10.3390/ijerph18062965

APA Style

Sayfutdinov, Z., Kumar, A., Nabirova, D., Gadoev, J., Turaev, L., Sultanov, S., Alaverdyan, S., & Parpieva, N. (2021). Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018. International Journal of Environmental Research and Public Health, 18(6), 2965. https://doi.org/10.3390/ijerph18062965

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop